Suhaskumar Patel

Mr. Suhaskumar Patel

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
NGNoopur Gandhi
Noopur Gandhi
AAAli Alaseem
Ali Alaseem
RDRohitas Deshmukh
Rohitas Deshmukh
APArtiben Patel
Artiben Patel
OAOmar Awad Alsaidan
Omar Awad Alsaidan
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati

5 February 2026 in Antonie van Leeuwenhoek
Verified
Journal Article
Closed access
PDF file
PVPremal Vaghela
Premal Vaghela
BDBhavarth Dave
Bhavarth Dave
ADAkshada Dabhade
Akshada Dabhade
RDRohitas Deshmukh
Rohitas Deshmukh
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
KDKiran Dudhat
Kiran Dudhat

29 May 2026 in Micromachines
Verified
Journal Article
Open access
PDF file
AMArjun Gokulan M
Arjun Gokulan M
SSSreejaa B S
Sreejaa B S
MKMohana Priya Kandan
Mohana Priya Kandan
NJNARAYANAN J
NARAYANAN J
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Dignesh KhuntDignesh Khunt
Dignesh Khunt
Background: A transdermal drug delivery system has significant benefits over conventional routes; however, its effectiveness is limited by the barrier properties of the stratum corneum. Dissolving microneedles (DMNs) have emerged as a minimally invasive strategy to enhance drug permeation while improving patient compliance. The integration of advanced fabrication techniques such as 3D printing enables precise control over microneedle geometry and reproducibility. Objective: This study aimed to fabricate and characterize pregabalin-loaded PVA/PVP dissolving microneedle arrays using a 3D-printing-assisted mold fabrication approach for efficient transdermal drug delivery. Methods: Microneedle master molds were fabricated using 3D printing, followed by replication using polydimethylsiloxane (PDMS) to obtain negative molds. Pregabalin-loaded bilayer microneedles were prepared using a micromolding technique with PVA/PVP polymers. The formulation was evaluated through rheological analysis, scanning electron microscopy (SEM), mechanical strength testing, insertion studies, swelling behavior, drug loading efficiency, Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and in vitro drug release studies. Results: The fabricated microneedles exhibited uniform geometry with sharp tips and no structural defects. Rheological analysis confirmed shear-thinning behavior suitable for mold filling. The microneedles demonstrated adequate mechanical strength (~3.3 N/needle) and efficient insertion into the parafilm model. Drug loading efficiency was high (92.4%), indicating effective encapsulation. FTIR analysis confirmed compatibility between drug and polymers, while DSC and XRD results indicated partial amorphization of pregabalin within the polymer matrix. The formulation showed a biphasic drug release profile with an initial burst followed by sustained release, achieving ~96.8% cumulative release over 24 h. Conclusions: The study successfully demonstrates a robust and reproducible 3D-printing-assisted approach for fabricating pregabalin-loaded dissolving microneedles. The developed system exhibited desirable mechanical, physicochemical, and drug release properties, highlighting its potential as an effective transdermal drug delivery platform.

26 August 2026 in Micromachines
Verified
Journal Article
Open access
PDF file
AMArjun Gokulan M
Arjun Gokulan M
NJNARAYANAN J
NARAYANAN J
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
KPKaran Prajapati
Karan Prajapati
SPSuhaskumar Patel
Suhaskumar Patel
Dissolving microneedles offers a minimally invasive approach for transdermal drug delivery by facilitating drug transport across the stratum corneum while overcoming several limitations associated with conventional routes of administration. Benzhydroxamic acid has demonstrated biochemical and computational evidence associated with inflammatory and pain-related pathways; however, its incorporation into a dissolving microneedle platform has not been extensively explored.This study aimed to fabricate and characterize benzhydroxamic acid-loaded dissolving microneedles using a 3D-printing-assisted mold fabrication approach for transdermal drug delivery. A stereolithography-based 3D-printed master mold was used to prepare a reverse polydimethylsiloxane mold. Benzhydroxamic acid-loaded dissolving microneedles were fabricated using a PVA/PVP polymeric matrix and evaluated for their physicochemical, mechanical, insertional, and drug-delivery characteristics. The developed microneedles exhibited shear-thinning behavior, uniform morphology, and satisfactory mechanical properties, with a compression force of 3.5 ± 0.01 N/needle and tensile strength of 3.84 ± 0.21 MPa. The formulation demonstrated a drug-loading efficiency of 94.6 ± 0.35% and effective insertion into the Parafilm® M skin-simulant model. In vitro drug release reached 97.24% over 24 h, while ex vivo skin permeation reached 94.83% over 24 h. FTIR and XRD analyses indicated successful incorporation of benzhydroxamic acid into the PVA/PVP matrix without major evidence of drug–polymer incompatibility. The findings demonstrate the feasibility of incorporating benzhydroxamic acid into a PVA/PVP dissolving microneedle platform using a 3D-printing-assisted mold fabrication approach. The developed system exhibited suitable physicochemical and mechanical characteristics, efficient drug loading, effective insertion, and satisfactory in vitro and ex vivo drug-delivery performance, supporting its potential as a transdermal drug delivery platform.

13 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NVNaveen Kumar V
Naveen Kumar V
CVChitra Vellapandian
Chitra Vellapandian
HPHimanshu Paliwal
Himanshu Paliwal
SPSuhaskumar Patel
Suhaskumar Patel
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Background: Due to chronic venous insufficiency, venous leg ulcers (VLUs) develop as chronic wounds characterized by impaired healing, persistent inflammation, and endothelial dysfunction. Nitrosative stress, mitochondrial damage, and tissue apoptosis caused by excess nitric oxide (NO) produced by iNOS in macrophages and fibroblasts are contributing factors in the chronic wound environment; therefore, pharmacological modulation of iNOS presents an attractive mechanistic target in chronic wound pathophysiology. Methods: Herein, we present the use of a structure-based computational strategy to assess the inhibition of tavaborole, a boron-based antifungal agent, against iNOS using human iNOS crystal structure (PDB ID: iNOS) by molecular docking using AutoDock 4.2, 500 ns simulation of molecular dynamics (MD), with equilibration within ~50 ns and analyses over full trajectory and binding free energy calculations through the MM-PBSA approach. Results: Docking studies showed favorable binding of tavaborole (–6.1 kcal/mol) in the catalytic domain, which stabilizes contacts with several key residues (CYS200, PRO350, PHE369, GLY371, TRP372, TYR373, and GLU377). MD trajectories for 1 ns showed stable structural configurations with negligible deviations (RMSD ≈ 0.44 ± 0.10 nm) and hydrogen bonding, and MM-PBSA analysis confirmed energetically favorable complex formation (ΔG_binding ≈ 18.38 ± 63.24 kJ/mol) similar to the control systems (L-arginine and 1400W). Conclusions: Taken together, these computational findings indicate that tavaborole can stably occupy the iNOS active site and interact with key catalytic residues, providing a mechanistic basis for further in vitro and ex vivo validation of its potential as an iNOS inhibitor to reduce nitrosative stress and restore endothelial homeostasis in venous leg ulcers, rather than direct therapeutic proof.

9 August 2026 in BioImpacts
Verified
Journal Article
Open access
PDF file
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
OAOmar Awad Alsaidan
Omar Awad Alsaidan
SASami Alzarea
Sami Alzarea
KDKiran Dudhat
Kiran Dudhat
CPCHANDRAKANTSING PARDESHI
CHANDRAKANTSING PARDESHI
Dignesh KhuntDignesh Khunt
Dignesh Khunt
Introduction: Skin cancer is one of the most prevalent malignancies worldwide, with incidence increasing by approximately 2–3% annually due to prolonged ultraviolet radiation exposure, genetic predisposition, and an ageing population. Conventional treatments, including oral, injectable, and topical therapies, are often limited by poor skin permeability, first-pass metabolism, systemic toxicity, and inadequate tumor targeting. Methods: This review systematically examines ethosomal drug delivery systems, focusing on their composition, mechanism of skin permeation, and formulation strategies. Key aspects such as phospholipid composition, ethanol concentration (20–45% w/w), preparation techniques, and interaction with tumor-altered skin barriers are critically analyzed. Results: Ethosomes, as deformable lipid vesicles, enhance transdermal drug delivery by fluidizing stratum corneum lipid lamellae, enabling deeper dermal penetration. Studies demonstrate improved drug localization, controlled release, and enhanced therapeutic efficacy in various skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. Applications in chemotherapy, photodynamic therapy, and immunotherapy show promising preclinical outcomes. Conclusion: Despite significant advancements and encouraging preclinical results, challenges such as formulation stability, scalability, regulatory considerations, and long-term safety must be addressed before ethosomal systems can achieve successful clinical translation in skin cancer therapy.